Rapid onset of action and reduced nasal hyperreactivity: new targets in allergic rhinitis management

ConclusionWith the most rapid onset of action and onset of clinically-relevant effect of any AR medication currently available, and proven efficacy in the treatment of NHR, MP-AzeFlu is an AR treatment which provides what patients want, and fits how patients manage their AR in real life.

http://link.springer.com/10.1186/s13601-018-0210-2

Source: Clinical and Translational Allergy - June 25, 2018 Category: Allergy & Immunology Source Type: research